Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

被引：0
|
作者：
Sanambar Sadighi
Mohammad Ali Mohagheghi
Ali Montazeri
Zahra Sadighi
机构：
[1] Tehran University of Medical Sciences,Cancer Research Center, Cancer Institute, Imam Hospital
[2] Iranian Institute for Health Sciences Research,undefined
来源：
BMC Cancer | / 6卷
关键词：
Gastric Cancer; Docetaxel; Epirubicin; Advanced Gastric Cancer; Group Physical Functioning;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine after radical gastrectomy for advanced gastric cancer
    Lee, H.
    Choi, Y.
    Hur, W.
    Kwon, H.
    Kim, M.
    Jung, G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S303 - S304
  • [32] QUALITY-OF-LIFE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER RECEIVING CHEMOTHERAPY - A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING 5-FU VERSUS 5-FU WITH LEUCOVORIN
    SULLIVAN, BA
    MCKINNIS, R
    LAUFMAN, LR
    [J]. PHARMACOTHERAPY, 1995, 15 (05): : 600 - 607
  • [33] Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC)
    Hitt, R.
    Grau, J. J.
    Lopez-Pousa, A.
    Berrocal, A.
    Garcia Giron, C.
    Irigoyen, A.
    Sastre, J.
    Martinez, J.
    Cortes-Funes, H.
    Cruz-Hernandez, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] A RANDOMIZED TRIAL OF CISPLATIN (CACP) + 5-FLUOROURACIL (5-FU) INFUSION AND CACP + 5-FU BOLUS FOR RECURRENT AND ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    KISH, JA
    ENSLEY, JF
    JACOBS, J
    WEAVER, A
    CUMMINGS, G
    ALSARRAF, M
    [J]. CANCER, 1985, 56 (12) : 2740 - 2744
  • [35] RANDOMIZED CLINICAL-STUDY WITH MMC AND 5-FU VS MMC, 5-FU AND PSK IN ADVANCED GASTRIC-CANCER
    NAKAO, I
    YOKOYAMA, T
    URUSHIZAKI, I
    WAKUI, A
    FURUE, H
    KOYAMA, Y
    KIMURA, K
    OGAWA, N
    SAITO, T
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1985, 7 (03): : 334 - 334
  • [36] Economic assessment of capecitabine/cisplatin versus 5-FU/cisplatin regimens in adjuvant treatment of advanced gastric cancer in Spain
    Safont, M.
    Darba, J.
    Restovic, G.
    Sastre, J.
    Bellmunt Molins, J.
    Gomez, M. A.
    Salgado, M.
    Vila, C.
    Ramirez De Arellano, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] ECONOMIC ASSESSMENT OF CAPECITABINE/CISPLATIN VERSUS 5-FU/CISPLATIN REGIMENS IN ADJUVANT TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN
    Darba, J.
    Restovic, G.
    Ramirez de Arellano, A.
    Safont, M.
    Sastre, J.
    Bellmunt, J.
    Gomez, M.
    Salgado, M.
    Vila, C.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 184 - 184
  • [38] 5-fluorouracil (5-FU) plasma exposure and outcome in patients receiving a TPF (taxotere, cisplatin, 5-FU) chemotherapy
    Legand, C.
    Blasco, H.
    Benz, I.
    Chapet, C.
    Le Guellec, C.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 25 - 25
  • [39] Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicincisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK).
    Roth, AD
    Maibach, R
    Falk, S
    Stupp, R
    Saletti, P
    Kaberle, D
    Borner, MM
    Honegger, HP
    Leslie, M
    Fazio, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 318S - 318S
  • [40] Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
    Pauligk, Claudia
    Tannapfel, Andrea
    Meiler, Johannes
    Luley, Kim Barbara
    Kopp, Hans-Georg
    Homann, Nils
    Hofheinz, Ralf Dieter
    Schmalenberg, Harald
    Probst, Stephan
    Haag, Georg Martin
    Egger, Matthias
    Behringer, Dirk M.
    Stoehlmacher, Jan
    Prasnikar, Nicole
    Block, Andreas
    Trojan, Jorg
    Koenigsmann, Michael
    Schmiegel, Wolff
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345